Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of AVT16 in Healthy Adult Subjects
NCT06400719Phase 1Completed
- Sponsor
- Alvotech
- Start
- May 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of emvistegrast in ulcerative colitis (UC) and Crohn's disease, sponsored by Alvotech. Primary endpoint: Incidence, nature and severity of Treatment Emergent Adverse Events at 18 weeks. Started May 2024; status: completed.
02
Drugs
emvistegrast
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06400719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06400719.